Hubbry Logo
AllergyAllergyMain
Open search
Allergy
Community hub
Allergy
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Allergy
Allergy
from Wikipedia

Allergy
Hives are a common allergic symptom.
SpecialtyImmunology
SymptomsRed eyes, itchy rash, vomiting, runny nose, shortness of breath, swelling, sneezing, and cough
TypesHay fever, food allergies, atopic dermatitis, allergic asthma, anaphylaxis[1]
CausesGenetic and environmental factors[2]
Diagnostic methodBased on symptoms, skin prick test, blood test[3]
Differential diagnosisFood intolerances, food poisoning[4]
PreventionEarly exposure to potential allergens[5]
TreatmentAvoiding known allergens, medications, allergen immunotherapy[6]
MedicationSteroids, antihistamines, epinephrine, mast cell stabilizers, antileukotrienes[6][7][8][9]
FrequencyCommon[10]

An allergy is an exaggerated immune response where the body mistakenly identifies an ordinarily harmless allergen as a threat.[11][12][13][14] Allergic reactions give rise to allergic diseases such as hay fever, allergic conjunctivitis, allergic asthma, atopic dermatitis, food allergies, and anaphylaxis.[1] Symptoms of allergic diseases may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling.[15][3][4]

Common allergens include pollen, certain foods, metals, insect stings, and medications.[11][2] The development of allergies is due to genetic and environmental factors.[2] The mechanism of allergic reactions involves immunoglobulin E antibodies (IgE) binding to an allergen and then to a receptor on mast cells or basophils, where they trigger the release of inflammatory chemicals such as histamine.[16] Diagnosis is typically based on a person's medical history.[3] Further testing of the skin or blood may be useful in certain cases.[3] Positive tests, however, may not necessarily mean there is a significant allergy to the substance in question.[17]

Early exposure of children to potential allergens may be protective.[5] Treatments for allergies include avoidance of known allergens and the use of medications such as steroids and antihistamines.[6] In severe reactions, injectable adrenaline (epinephrine) is recommended.[7] Allergen immunotherapy, which gradually exposes people to larger and larger amounts of allergen, is useful for some types of allergies such as hay fever and reactions to insect bites.[6] Its use in food allergies is unclear.[6]

Allergies are common.[10] In the developed world, about 20% of people are affected by allergic rhinitis,[18] food allergy affects 10% of adults and 8% of children,[19] and about 20% have or have had atopic dermatitis at some point in time.[20] Depending on the country, about 1–18% of people have asthma.[21][22] Anaphylaxis occurs in between 0.05–2% of people.[23] Rates of many allergic diseases appear to be increasing.[7][24][25] The word "allergy" was first used by Clemens von Pirquet in 1906.[2]

Signs and symptoms

[edit]
Affected organ Common signs and symptoms
Nose Swelling of the nasal mucosa (allergic rhinitis) runny nose, sneezing
Sinuses Allergic sinusitis
Eyes Redness and itching of the conjunctiva (allergic conjunctivitis, watery)
Airways Sneezing, coughing, bronchoconstriction, wheezing and dyspnea, sometimes outright attacks of asthma, in severe cases the airway constricts due to swelling known as laryngeal edema
Ears Feeling of fullness, possibly pain, and impaired hearing due to the lack of eustachian tube drainage.
Skin Rashes, such as eczema and hives (urticaria)
Gastrointestinal tract Abdominal pain, bloating, vomiting, diarrhea

Many allergens such as dust or pollen are airborne particles. In these cases, symptoms arise in areas in contact with air, such as the eyes, nose, and lungs. For instance, allergic rhinitis, also known as hay fever, causes irritation of the nose, sneezing, itching, and redness of the eyes.[26] Inhaled allergens can also lead to increased production of mucus in the lungs, shortness of breath, coughing, and wheezing.[27]

Aside from these ambient allergens, allergic reactions can result from foods, insect stings, and reactions to medications like aspirin and antibiotics such as penicillin. Symptoms of food allergy include abdominal pain, bloating, vomiting, diarrhea, itchy skin, and hives. Food allergies rarely cause respiratory (asthmatic) reactions, or rhinitis.[28] Insect stings, food, antibiotics, and certain medicines may produce a systemic allergic response that is also called anaphylaxis; multiple organ systems can be affected, including the digestive system, the respiratory system, and the circulatory system.[29][30][31] Depending on the severity, anaphylaxis can include skin reactions, bronchoconstriction, swelling, low blood pressure, coma, and death. This type of reaction can be triggered suddenly, or the onset can be delayed. The nature of anaphylaxis is such that the reaction can seem to be subsiding but may recur throughout a period of time.[31]

Skin

[edit]

Substances that come into contact with the skin, such as latex, are also common causes of allergic reactions, known as contact dermatitis or eczema.[32] Skin allergies frequently cause rashes, or swelling and inflammation within the skin, in what is known as a "wheal and flare" reaction characteristic of hives and angioedema.[33]

With insect stings, a large local reaction may occur in the form of an area of skin redness greater than 10 cm in size that can last one to two days.[34] This reaction may also occur after immunotherapy.[35]

The way the body responds to foreign invaders on the molecular level is similar to how allergens are treated even on the skin. The skin forms an effective barrier to the entry of most allergens but this barrier cannot withstand everything that comes at it. A situation such as an insect sting can breach the barrier and inject allergen to the affected spot. When an allergen enters the epidermis or dermis, it triggers a localized allergic reaction which activates the mast cells in the skin resulting in an immediate increase in vascular permeability, leading to fluid leakage and swelling in the affected area.[36] Mast-cell activation also stimulates a skin lesion called the wheal-and-flare reaction.[37] This is when the release of chemicals from local nerve endings by a nerve axon reflex, causes the vasodilatations of surrounding cutaneous blood vessels, which causes redness of the surrounding skin.[37]

As a part of the allergy response, the body has developed a secondary response which in some individuals causes a more widespread and sustained edematous response.[36] This usually occurs about 8 hours after the allergen originally comes in contact with the skin. When an allergen is ingested, a dispersed form of wheal-and-flare reaction, known as urticaria or hives will appear when the allergen enters the bloodstream and eventually reaches the skin.[36][38] The way the skin reacts to different allergens gives allergists the upper hand and allows them to test for allergies by injecting a very small amount of an allergen into the skin.[36] Even though these injections are very small and local, they still pose the risk of causing systematic anaphylaxis.[36]

Cause

[edit]

Risk factors for allergies can be placed in two broad categories, namely host and environmental factors.[39] Host factors include heredity, sex, race, and age, with heredity being by far the most significant. However, there has been a recent increase in the incidence of allergic disorders that cannot be explained by genetic factors alone. Four major environmental candidates are alterations in exposure to infectious diseases during early childhood, environmental pollution, allergen levels, and dietary changes.[40]

Dust mites

[edit]

Dust mite allergy, also known as house dust allergy, is a sensitization and allergic reaction to the droppings of house dust mites. The allergy is common[41][42] and can trigger allergic reactions such as asthma, eczema, or itching. The mite's gut contains potent digestive enzymes (notably peptidase 1) that persist in their feces and are major inducers of allergic reactions such as wheezing. The mite's exoskeleton can also contribute to allergic reactions. Unlike scabies mites or skin follicle mites, house dust mites do not burrow under the skin and are not parasitic.[43]

Foods

[edit]

A wide variety of foods can cause allergic reactions, but 90% of allergic responses to foods are caused by cow's milk, soy, eggs, wheat, peanuts, tree nuts, fish, and shellfish.[44] Other food allergies, affecting less than 1 person per 10,000 population, may be considered "rare".[45] The most common food allergy in the US population is a sensitivity to crustacea.[45] Although peanut allergies are notorious for their severity, peanut allergies are not the most common food allergy in adults or children. Severe or life-threatening reactions may be triggered by other allergens and are more common when combined with asthma.[44]

Rates of allergies differ between adults and children. Children can sometimes outgrow peanut allergies. Egg allergies affect one to two percent of children but are outgrown by about two-thirds of children by the age of 5.[46] The sensitivity is usually to proteins in the white, rather than the yolk.[47]

Milk-protein allergies—distinct from lactose intolerance—are most common in children.[48] Approximately 60% of milk-protein reactions are immunoglobulin E–mediated, with the remaining usually attributable to inflammation of the colon.[49] Some people are unable to tolerate milk from goats or sheep as well as from cows, and many are also unable to tolerate dairy products such as cheese. Roughly 10% of children with a milk allergy will have a reaction to beef.[50] Lactose intolerance, a common reaction to milk, is not a form of allergy at all, but due to the absence of an enzyme in the digestive tract.[51]

Those with tree nut allergies may be allergic to one or many tree nuts, including pecans, pistachios, and walnuts.[47] In addition, seeds, including sesame seeds and poppy seeds, contain oils in which protein is present, which may elicit an allergic reaction.[47]

Allergens can be transferred from one food to another through genetic engineering; however, genetic modification can also remove allergens. Little research has been done on the natural variation of allergen concentrations in unmodified crops.[52][53]

Latex

[edit]

Latex can trigger an IgE-mediated cutaneous, respiratory, and systemic reaction. The prevalence of latex allergy in the general population is believed to be less than one percent. In a hospital study, 1 in 800 surgical patients (0.125 percent) reported latex sensitivity, although the sensitivity among healthcare workers is higher, between seven and ten percent. Researchers attribute this higher level to the exposure of healthcare workers to areas with significant airborne latex allergens, such as operating rooms, intensive-care units, and dental suites. These latex-rich environments may sensitize healthcare workers who regularly inhale allergenic proteins.[54]

The most prevalent response to latex is an allergic contact dermatitis, a delayed hypersensitive reaction appearing as dry, crusted lesions. This reaction usually lasts 48–96 hours. Sweating or rubbing the area under the glove aggravates the lesions, possibly leading to ulcerations.[54] Anaphylactic reactions occur most often in sensitive patients who have been exposed to a surgeon's latex gloves during abdominal surgery, but other mucosal exposures, such as dental procedures, can also produce systemic reactions.[54]

Latex and banana sensitivity may cross-react. Furthermore, those with latex allergy may also have sensitivities to avocado, kiwifruit, and chestnut.[55] These people often have perioral itching and local urticaria. Only occasionally have these food-induced allergies induced systemic responses. Researchers suspect that the cross-reactivity of latex with banana, avocado, kiwifruit, and chestnut occurs because latex proteins are structurally homologous with some other plant proteins.[54]

Medications

[edit]

About 10% of people report that they are allergic to penicillin; however, of that 10%, 90% turn out not to be.[56] Serious allergies only occur in about 0.03%.[56]

Insect stings

[edit]

One of the main sources of human allergies is insects. An allergy to insects can be brought on by bites, stings, ingestion, and inhalation.[57]

Toxins interacting with proteins

[edit]

Another non-food protein reaction, urushiol-induced contact dermatitis, originates after contact with poison ivy, eastern poison oak, western poison oak, or poison sumac. Urushiol, which is not itself a protein, acts as a hapten and chemically reacts with, binds to, and changes the shape of integral membrane proteins on exposed skin cells. The immune system does not recognize the affected cells as normal parts of the body, causing a T-cell-mediated immune response.[58]

Of these poisonous plants, sumac is the most virulent.[59][60] The resulting dermatological response to the reaction between urushiol and membrane proteins includes redness, swelling, papules, vesicles, blisters, and streaking.[61]

Estimates vary on the population fraction that will have an immune system response. Approximately 25% of the population will have a strong allergic response to urushiol. In general, approximately 80–90% of adults will develop a rash if they are exposed to 0.0050 mg (7.7×10−5 gr) of purified urushiol, but some people are so sensitive that it takes only a molecular trace on the skin to initiate an allergic reaction.[62]

Genetics

[edit]

Allergic diseases are strongly familial; identical twins are likely to have the same allergic diseases about 70% of the time; the same allergy occurs about 40% of the time in non-identical twins.[63] Allergic parents are more likely to have allergic children[64] and those children's allergies are likely to be more severe than those in children of non-allergic parents. Some allergies, however, are not consistent along genealogies; parents who are allergic to peanuts may have children who are allergic to ragweed. The likelihood of developing allergies is inherited and related to an irregularity in the immune system, but the specific allergen is not.[64]

The risk of allergic sensitization and the development of allergies varies with age, with young children most at risk.[65] Several studies have shown that IgE levels are highest in childhood and fall rapidly between the ages of 10 and 30 years.[65] The peak prevalence of hay fever is highest in children and young adults and the incidence of asthma is highest in children under 10.[66]

Ethnicity may play a role in some allergies; however, racial factors have been difficult to separate from environmental influences and changes due to migration.[64] It has been suggested that different genetic loci are responsible for asthma, to be specific, in people of European, Hispanic, Asian, and African origins.[67]

Researchers have worked to characterize genes involved in inflammation and the maintenance of mucosal integrity. The identified genes associated with allergic disease severity, progression, and development primarily function in four areas: regulating inflammatory responses (IFN-α, TLR-1, IL-13, IL-4, IL-5, HLA-G, iNOS), maintaining vascular endothelium and mucosal lining (FLG, PLAUR, CTNNA3, PDCH1, COL29A1), mediating immune cell function (PHF11, H1R, HDC, TSLP, STAT6, RERE, PPP2R3C), and influencing susceptibility to allergic sensitization (e.g., ORMDL3, CHI3L1).[68]

Multiple studies have investigated the genetic profiles of individuals with predispositions to and experiences of allergic diseases, revealing a complex polygenic architecture. Specific genetic loci, such as MIIP, CXCR4, SCML4, CYP1B1, ICOS, and LINC00824, have been directly associated with allergic disorders.[68] Additionally, some loci show pleiotropic effects, linking them to both autoimmune and allergic conditions, including PRDM2, G3BP1, HBS1L, and POU2AF1.[68] These genes engage in shared inflammatory pathways across various epithelial tissues—such as the skin, esophagus, vagina, and lung—highlighting common genetic factors that contribute to the pathogenesis of asthma and other allergic diseases.[68]

In atopic patients, transcriptome studies have identified IL-13-related pathways as key for eosinophilic airway inflammation and remodeling. That causes the body to experience the type of airflow restriction of allergic asthma.[68] Expression of genes was quite variable: genes associated with inflammation were found almost exclusively in superficial airways, while genes related to airway remodeling were mainly present in endobronchial biopsy specimens.[68] This enhanced gene profile was similar across multiple sample sizes – nasal brushing, sputum, endobronchial brushing – demonstrating the importance of eosinophilic inflammation, mast cell degranulation and group 3 innate lymphoid cells in severe adult-onset asthma.[68] IL-13 is an immunoregulatory cytokine that is made mostly by activated T-helper 2 (Th2) cells.[69] It is an important cytokine for many steps in B-cell maturation and differentiation, since it increases CD23 and MHC class II molecules, and aids in B-cell isotype switching to IgE.[68][69] IL-13 also suppresses macrophage function by reducing the release of pro-inflammatory cytokines and chemokines.[69][70] The more striking thing is that IL-13 is the prime mover in allergen-induced asthma via pathways that are independent of IgE and eosinophils.[69]

Hygiene hypothesis

[edit]

Allergic diseases are caused by inappropriate immunological responses to harmless antigens driven by a TH2-mediated immune response. Many bacteria and viruses elicit a TH1-mediated immune response, which down-regulates TH2 responses. The first proposed mechanism of action of the hygiene hypothesis was that insufficient stimulation of the TH1 arm of the immune system leads to an overactive TH2 arm, which in turn leads to allergic disease.[71] In other words, individuals living in too sterile an environment are not exposed to enough pathogens to keep the immune system busy. Since our bodies evolved to deal with a certain level of such pathogens, when they are not exposed to this level, the immune system will attack harmless antigens, and thus normally benign microbial objects—like pollen—will trigger an immune response.[72]

The hygiene hypothesis was developed to explain the observation that hay fever and eczema, both allergic diseases, were less common in children from larger families, which were, it is presumed, exposed to more infectious agents through their siblings, than in children from families with only one child.[73] It is used to explain the increase in allergic diseases that have been seen since industrialization, and the higher incidence of allergic diseases in more developed countries.[74] The hygiene hypothesis has now expanded to include exposure to symbiotic bacteria and parasites as important modulators of immune system development, along with infectious agents.[75]

Epidemiological data support the hygiene hypothesis. Studies have shown that various immunological and autoimmune diseases are much less common in the developing world than the industrialized world, and that immigrants to the industrialized world from the developing world increasingly develop immunological disorders in relation to the length of time since arrival in the industrialized world.[76] Longitudinal studies in the third world demonstrate an increase in immunological disorders as a country grows more affluent and, it is presumed, cleaner.[77] The use of antibiotics in the first year of life has been linked to asthma and other allergic diseases.[78] The use of antibacterial cleaning products has also been associated with higher incidence of asthma, as has birth by caesarean section rather than vaginal birth.[79][80]

Stress

[edit]

Chronic stress can aggravate allergic conditions. This has been attributed to a T helper 2 (TH2)-predominant response driven by suppression of interleukin 12 by both the autonomic nervous system and the hypothalamic–pituitary–adrenal axis. Stress management in highly susceptible individuals may improve symptoms.[81]

Other environmental factors

[edit]

Allergic diseases are more common in industrialized countries than in countries that are more traditional or agricultural, and there is a higher rate of allergic disease in urban populations versus rural populations, although these differences are becoming less defined.[82] Historically, the trees planted in urban areas were predominantly male to prevent litter from seeds and fruits, but the high ratio of male trees causes high pollen counts, a phenomenon that horticulturist Tom Ogren has called "botanical sexism".[83]

Alterations in exposure to microorganisms is another plausible explanation, at present, for the increase in atopic allergy.[40] Endotoxin exposure reduces release of inflammatory cytokines such as TNF-α, IFNγ, interleukin-10, and interleukin-12 from white blood cells (leukocytes) that circulate in the blood.[84] Certain microbe-sensing proteins, known as Toll-like receptors, found on the surface of cells in the body are also thought to be involved in these processes.[85]

Parasitic worms and similar parasites are present in untreated drinking water in developing countries, and were present in the water of developed countries until the routine chlorination and purification of drinking water supplies.[86] Recent research has shown that some common parasites, such as intestinal worms (e.g., hookworms), secrete chemicals into the gut wall (and, hence, the bloodstream) that suppress the immune system and prevent the body from attacking the parasite.[87] This gives rise to a new slant on the hygiene hypothesis theory—that co-evolution of humans and parasites has led to an immune system that functions correctly only in the presence of the parasites. Without them, the immune system becomes unbalanced and oversensitive.[88]

In particular, research suggests that allergies may coincide with the delayed establishment of gut flora in infants.[89] However, the research to support this theory is conflicting, with some studies performed in China and Ethiopia showing an increase in allergy in people infected with intestinal worms.[82] Clinical trials have been initiated to test the effectiveness of helminthic therapy with certain worms in treating some allergies.[90] It may be that the term 'parasite' could turn out to be inappropriate, and in fact a hitherto unsuspected symbiosis is at work.[90]

Pathophysiology

[edit]
A summary diagram that explains how allergy develops
Tissues affected in allergic inflammation

Acute response

[edit]
Degranulation process in allergy. Second exposure to allergen. 1 – antigen; 2 – IgE antibody; 3 – FcεRI receptor; 4 – preformed mediators (histamine, proteases, chemokines, heparin); 5granules; 6mast cell; 7 – newly formed mediators (prostaglandins, leukotrienes, thromboxanes, PAF).

In the initial stages of allergy, a type I hypersensitivity reaction against an allergen encountered for the first time and presented by a professional antigen-presenting cell causes a response in a type of immune cell called a TH2 lymphocyte, a subset of T cells that produce a cytokine called interleukin-4 (IL-4). These TH2 cells interact with other lymphocytes called B cells, whose role is production of antibodies. Coupled with signals provided by IL-4, this interaction stimulates the B cell to begin production of a large amount of a particular type of antibody known as IgE. Secreted IgE circulates in the blood and binds to an IgE-specific receptor (a kind of Fc receptor called FcεRI) on the surface of other kinds of immune cells called mast cells and basophils, which are both involved in the acute inflammatory response. The IgE-coated cells, at this stage, are sensitized to the allergen.[40]

If later exposure to the same allergen occurs, the allergen can bind to the IgE molecules held on the surface of the mast cells or basophils. Cross-linking of the IgE and Fc receptors occurs when more than one IgE-receptor complex interacts with the same allergenic molecule and activates the sensitized cell. Activated mast cells and basophils undergo a process called degranulation, during which they release histamine and other inflammatory chemical mediators (cytokines, interleukins, leukotrienes, and prostaglandins) from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve stimulation, and smooth muscle contraction.

This results in rhinorrhea, itchiness, dyspnea, and anaphylaxis. Depending on the individual, allergen, and mode of introduction, the symptoms can be system-wide (classical anaphylaxis) or localized to specific body systems. Asthma is localized to the respiratory system and eczema is localized to the dermis.[40]

Late-phase response

[edit]

After the chemical mediators of the acute response subside, late-phase responses can often occur. This is due to the migration of other leukocytes such as neutrophils, lymphocytes, eosinophils, and macrophages to the initial site. The reaction is usually seen 2–24 hours after the original reaction.[91] Cytokines from mast cells may play a role in the persistence of long-term effects. Late-phase responses seen in asthma are slightly different from those seen in other allergic responses, although they are still caused by release of mediators from eosinophils and are still dependent on activity of TH2 cells.[92]

Allergic contact dermatitis

[edit]

Although allergic contact dermatitis is termed an "allergic" reaction (which usually refers to type I hypersensitivity), its pathophysiology involves a reaction that more correctly corresponds to a type IV hypersensitivity reaction.[93] In type IV hypersensitivity, there is activation of certain types of T cells (CD8+) that destroy target cells on contact, as well as activated macrophages that produce hydrolytic enzymes.[94]

Diagnosis

[edit]
An allergy testing machine being operated in a diagnostic immunology lab

Effective management of allergic diseases relies on the ability to make an accurate diagnosis.[95] Allergy testing can help confirm or rule out allergies.[96][97] Correct diagnosis, counseling, and avoidance advice based on valid allergy test results reduce the incidence of symptoms and need for medications, and improve quality of life.[96] To assess the presence of allergen-specific IgE antibodies, two different methods can be used: a skin prick test, or an allergy blood test. Both methods are recommended, and they have similar diagnostic value.[97][98]

Skin prick tests and blood tests are equally cost-effective, and health economic evidence shows that both tests were cost-effective compared with no test.[96] Early and more accurate diagnoses save cost due to reduced consultations, referrals to secondary care, misdiagnosis, and emergency admissions.[99]

Allergy undergoes dynamic changes over time. Regular allergy testing of relevant allergens provides information on if and how patient management can be changed to improve health and quality of life. Annual testing is often the practice for determining whether allergy to milk, egg, soy, and wheat have been outgrown, and the testing interval is extended to 2–3 years for allergy to peanut, tree nuts, fish, and crustacean shellfish.[97] Results of follow-up testing can guide decision-making regarding whether and when it is safe to introduce or re-introduce allergenic food into the diet.[100]

Skin prick testing

[edit]
Skin testing on arm
Skin testing on back

Skin testing is also known as "puncture testing" and "prick testing" due to the series of tiny punctures or pricks made into the patient's skin. Tiny amounts of suspected allergens and/or their extracts (e.g., pollen, grass, mite proteins, peanut extract) are introduced to sites on the skin marked with pen or dye (the ink/dye should be carefully selected, lest it cause an allergic response itself). A negative and positive control are also included for comparison (eg, negative is saline or glycerin; positive is histamine). A small plastic or metal device is used to puncture or prick the skin. Sometimes, the allergens are injected "intradermally" into the patient's skin, with a needle and syringe. Common areas for testing include the inside forearm and the back.

If the patient is allergic to the substance, then a visible inflammatory reaction will usually occur within 30 minutes. This response will range from slight reddening of the skin to a full-blown hive (called "wheal and flare") in more sensitive patients similar to a mosquito bite. Interpretation of the results of the skin prick test is normally done by allergists on a scale of severity, with +/− meaning borderline reactivity, and 4+ being a large reaction. Increasingly, allergists are measuring and recording the diameter of the wheal and flare reaction. Interpretation by well-trained allergists is often guided by relevant literature.[101]

In general, a positive response is interpreted when the wheal of an antigen is ≥3mm larger than the wheal of the negative control (eg, saline or glycerin).[102] Some patients may believe they have determined their own allergic sensitivity from observation, but a skin test has been shown to be much better than patient observation to detect allergy.[103]

If a serious life-threatening anaphylactic reaction has brought a patient in for evaluation, some allergists will prefer an initial blood test prior to performing the skin prick test. Skin tests may not be an option if the patient has widespread skin disease or has taken antihistamines in the last several days.

Patch testing

[edit]
Patch test

Patch testing is a method used to determine if a specific substance causes allergic inflammation of the skin. It tests for delayed reactions. It is used to help ascertain the cause of skin contact allergy or contact dermatitis. Adhesive patches, usually treated with several common allergic chemicals or skin sensitizers, are applied to the back. The skin is then examined for possible local reactions at least twice, usually at 48 hours after application of the patch, and again two or three days later.

Blood testing

[edit]

An allergy blood test is quick and simple and can be ordered by a licensed health care provider (e.g., an allergy specialist) or general practitioner. Unlike skin-prick testing, a blood test can be performed irrespective of age, skin condition, medication, symptom, disease activity, and pregnancy. Adults and children of any age can get an allergy blood test. For babies and very young children, a single needle stick for allergy blood testing is often gentler than several skin pricks.

An allergy blood test is available through most laboratories. A sample of the patient's blood is sent to a laboratory for analysis, and the results are sent back a few days later. Multiple allergens can be detected with a single blood sample. Allergy blood tests are very safe since the person is not exposed to any allergens during the testing procedure. After the onset of anaphylaxis or a severe allergic reaction, guidelines recommend emergency departments obtain a time-sensitive blood test to determine blood tryptase levels and assess for mast cell activation.[104]

The test measures the concentration of specific IgE antibodies in the blood. Quantitative IgE test results increase the possibility of ranking how different substances may affect symptoms. A rule of thumb is that the higher the IgE antibody value, the greater the likelihood of symptoms. Allergens found at low levels that today do not result in symptoms cannot help predict future symptom development. The quantitative allergy blood result can help determine what a patient is allergic to, help predict and follow the disease development, estimate the risk of a severe reaction, and explain cross-reactivity.[105][106]

A low total IgE level is not adequate to rule out sensitization to commonly inhaled allergens.[107] Statistical methods, such as ROC curves, predictive value calculations, and likelihood ratios have been used to examine the relationship of various testing methods to each other. These methods have shown that patients with a high total IgE have a high probability of allergic sensitization, but further investigation with allergy tests for specific IgE antibodies for a carefully chosen of allergens is often warranted.

Laboratory methods to measure specific IgE antibodies for allergy testing include enzyme-linked immunosorbent assay (ELISA, or EIA),[108] radioallergosorbent test (RAST),[108] fluorescent enzyme immunoassay (FEIA),[109] and chemiluminescence immunoassay (CLIA).[110][111]

Other testing

[edit]

Challenge testing: Challenge testing is when tiny amounts of a suspected allergen are introduced to the body orally, through inhalation, or via other routes. Except for testing food and medication allergies, challenges are rarely performed. When this type of testing is chosen, it must be closely supervised by an allergist.

Elimination/challenge tests: This testing method is used most often with foods or medicines. A patient with a suspected allergen is instructed to modify his diet to totally avoid that allergen for a set time. If the patient experiences significant improvement, he may then be "challenged" by reintroducing the allergen, to see if symptoms are reproduced.

Unreliable tests: There are other types of allergy testing methods that are unreliable, including applied kinesiology (allergy testing through muscle relaxation), cytotoxicity testing, urine autoinjection, skin titration (Rinkel method), and provocative and neutralization (subcutaneous) testing or sublingual provocation.[112]

Differential diagnosis

[edit]

Before a diagnosis of allergic disease can be confirmed, other plausible causes of the presenting symptoms must be considered.[113] Vasomotor rhinitis, for example, is one of many illnesses that share symptoms with allergic rhinitis, underscoring the need for professional differential diagnosis.[114] Once a diagnosis of asthma, rhinitis, anaphylaxis, or other allergic disease has been made, there are several methods for discovering the causative agent of that allergy.

Prevention

[edit]

Giving peanut products early in childhood may decrease the risk of allergies, and only breastfeeding during at least the first few months of life may decrease the risk of allergic dermatitis.[115][116] There is little evidence that a mother's diet during pregnancy or breastfeeding affects the risk of allergies,[115] although there has been some research to show that irregular cow's milk exposure might increase the risk of cow's milk allergy.[117] There is some evidence that delayed introduction of certain foods is useful,[115] and that early exposure to potential allergens may actually be protective.[5]

Fish oil supplementation during pregnancy is associated with a lower risk of food sensitivities.[116] Probiotic supplements during pregnancy or infancy may help to prevent atopic dermatitis.[118][119]

Management

[edit]

Management of allergies typically involves avoiding the allergy trigger and taking medications to improve the symptoms.[6] Allergen immunotherapy may be useful for some types of allergies.[6]

Medication

[edit]

Several medications may be used to block the action of allergic mediators, or to prevent activation of cells and degranulation processes. These include antihistamines, glucocorticoids, epinephrine (adrenaline), mast cell stabilizers, and antileukotriene agents are common treatments of allergic diseases.[120] Anticholinergics, decongestants, and other compounds thought to impair eosinophil chemotaxis are also commonly used. Although rare, the severity of anaphylaxis often requires epinephrine injection, and where medical care is unavailable, a device known as an epinephrine autoinjector may be used.[31]

Immunotherapy

[edit]
Anti-allergy immunotherapy

Allergen immunotherapy is useful for environmental allergies, allergies to insect bites, and asthma.[6][121] Its benefit for food allergies is unclear and thus not recommended.[6] Immunotherapy involves exposing people to larger and larger amounts of allergen in an effort to change the immune system's response.[6]

Meta-analyses have found that injections of allergens under the skin is effective in the treatment in allergic rhinitis in children[122][123] and in asthma.[121] The benefits may last for years after treatment is stopped.[124] It is generally safe and effective for allergic rhinitis and conjunctivitis, allergic forms of asthma, and stinging insects.[125]

To a lesser extent, the evidence also supports the use of sublingual immunotherapy for rhinitis and asthma.[124] For seasonal allergies the benefit is small.[126] In this form the allergen is given under the tongue and people often prefer it to injections.[124] Immunotherapy is not recommended as a stand-alone treatment for asthma.[124]

Alternative medicine

[edit]

An experimental treatment, enzyme potentiated desensitization (EPD), has been tried for decades but is not generally accepted as effective.[127] EPD uses dilutions of allergen and an enzyme, beta-glucuronidase, to which T-regulatory lymphocytes are supposed to respond by favoring desensitization, or down-regulation, rather than sensitization. EPD has also been tried for the treatment of autoimmune diseases, but evidence does not show effectiveness.[127]

A review found no effectiveness of homeopathic treatments and no difference compared with placebo. The authors concluded that based on rigorous clinical trials of all types of homeopathy for childhood and adolescence ailments, there is no convincing evidence that supports the use of homeopathic treatments.[128]

According to the National Center for Complementary and Integrative Health, U.S., the evidence is relatively strong that saline nasal irrigation and butterbur are effective, when compared to other alternative medicine treatments, for which the scientific evidence is weak, negative, or nonexistent, such as honey, acupuncture, omega 3's, probiotics, astragalus, capsaicin, grape seed extract, Pycnogenol, quercetin, spirulina, stinging nettle, tinospora, or guduchi. [129][130]

Epidemiology

[edit]

The allergic diseases—hay fever and asthma—have increased in the Western world over the past 2–3 decades.[131] Increases in allergic asthma and other atopic disorders in industrialized nations, it is estimated, began in the 1960s and 1970s, with further increases occurring during the 1980s and 1990s,[132] although some suggest that a steady rise in sensitization has been occurring since the 1920s.[133] The number of new cases per year of atopy in developing countries has, in general, remained much lower.[132]

Allergic conditions: Statistics and epidemiology
Allergy type United States United Kingdom[134]
Allergic rhinitis 35.9 million[135] (about 11% of the population[136]) 3.3 million (about 5.5% of the population[137])
Asthma 10 million have allergic asthma (about 3% of the population). The prevalence of asthma increased 75% from 1980 to 1994. Asthma prevalence is 39% higher in African Americans than in Europeans.[138] 5.7 million (about 9.4%). In six- and seven-year-olds asthma increased from 18.4% to 20.9% over five years, during the same time the rate decreased from 31% to 24.7% in 13- to 14-year-olds.
Atopic eczema About 9% of the population. Between 1960 and 1990, prevalence has increased from 3% to 10% in children.[139] 5.8 million (about 1% severe).
Anaphylaxis At least 40 deaths per year due to insect venom. About 400 deaths due to penicillin anaphylaxis. About 220 cases of anaphylaxis and 3 deaths per year are due to latex allergy.[140] An estimated 150 people die annually from anaphylaxis due to food allergy.[141] Between 1999 and 2006, 48 deaths occurred in people ranging from five months to 85 years old.
Insect venom Around 15% of adults have mild, localized allergic reactions. Systemic reactions occur in 3% of adults and less than 1% of children.[142] Unknown
Drug allergies Anaphylactic reactions to penicillin cause 400 deaths per year. Unknown
Food allergies 7.6% of children and 10.8% of adults.[143] Peanut and/or tree nut (e.g. walnut) allergy affects about three million Americans, or 1.1% of the population.[141] 5–7% of infants and 1–2% of adults. A 117.3% increase in peanut allergies was observed from 2001 to 2005, an estimated 25,700 people in England are affected.
Multiple allergies (Asthma, eczema and allergic rhinitis together) Unknown 2.3 million (about 3.7%), prevalence has increased by 48.9% between 2001 and 2005.[144]

Changing frequency

[edit]

Although genetic factors govern susceptibility to atopic disease, increases in atopy have occurred within too short a period to be explained by a genetic change in the population, thus pointing to environmental or lifestyle changes.[132] Several hypotheses have been identified to explain this increased rate. Increased exposure to perennial allergens may be due to housing changes and increased time spent indoors, and a decreased activation of a common immune control mechanism may be caused by changes in cleanliness[145] or hygiene, and exacerbated by dietary changes, obesity, and decline in physical exercise.[131] The hygiene hypothesis maintains[146] that high living standards and hygienic conditions exposes children to fewer infections. It is thought that reduced bacterial and viral infections early in life direct the maturing immune system away from TH1 type responses, leading to unrestrained TH2 responses that allow for an increase in allergy.[88][147]

Changes in rates and types of infection alone, however, have been unable to explain the observed increase in allergic disease, and recent evidence has focused attention on the importance of the gastrointestinal microbial environment. Evidence has shown that exposure to food and fecal-oral pathogens, such as hepatitis A, Toxoplasma gondii, and Helicobacter pylori (which also tend to be more prevalent in developing countries), can reduce the overall risk of atopy by more than 60%,[148] and an increased rate of parasitic infections has been associated with a decreased prevalence of asthma.[149] It is speculated that these infections exert their effect by critically altering TH1/TH2 regulation.[150] Important elements of newer hygiene hypotheses also include exposure to endotoxins, exposure to pets and growing up on a farm.[150]

History

[edit]

Some symptoms attributable to allergic diseases are mentioned in ancient sources.[151] Particularly, three members of the Roman Julio-Claudian dynasty (Augustus, Claudius and Britannicus) are suspected to have a family history of atopy.[151][152] The concept of "allergy" was originally introduced in 1906 by the Viennese pediatrician Clemens von Pirquet, after he noticed that patients who had received injections of horse serum or smallpox vaccine usually had quicker, more severe reactions to second injections.[153] Pirquet called this phenomenon "allergy" from the Ancient Greek words ἄλλος allos meaning "other" and ἔργον ergon meaning "work".[154]

All forms of hypersensitivity used to be classified as allergies, and all were thought to be caused by an improper activation of the immune system. Later, it became clear that several different disease mechanisms were implicated, with a common link to a disordered activation of the immune system. In 1963, a new classification scheme was designed by Philip Gell and Robin Coombs that described four types of hypersensitivity reactions, known as Type I to Type IV hypersensitivity.[155]

With this new classification, the word allergy, sometimes clarified as a true allergy, was restricted to type I hypersensitivities (also called immediate hypersensitivity), which are characterized as rapidly developing reactions involving IgE antibodies.[156]

A major breakthrough in understanding the mechanisms of allergy was the discovery of the antibody class labeled immunoglobulin E (IgE). IgE was simultaneously discovered in 1966–67 by two independent groups:[157] Ishizaka's team at the Children's Asthma Research Institute and Hospital in Denver, USA,[158] and by Gunnar Johansson and Hans Bennich in Uppsala, Sweden.[159] Their joint paper was published in April 1969.[160]

Diagnosis

[edit]

Radiometric assays include the radioallergosorbent test (RAST test) method, which uses IgE-binding (anti-IgE) antibodies labeled with radioactive isotopes for quantifying the levels of IgE antibody in the blood.[161]

The RAST methodology was invented and marketed in 1974 by Pharmacia Diagnostics AB, Uppsala, Sweden, and the acronym RAST is actually a brand name. In 1989, Pharmacia Diagnostics AB replaced it with a superior test named the ImmunoCAP Specific IgE blood test, which uses the newer fluorescence-labeled technology.[162]

American College of Allergy Asthma and Immunology (ACAAI) and the American Academy of Allergy Asthma and Immunology (AAAAI) issued the Joint Task Force Report "Pearls and pitfalls of allergy diagnostic testing" in 2008, and is firm in its statement that the term RAST is now obsolete:

The term RAST became a colloquialism for all varieties of (in vitro allergy) tests. This is unfortunate because it is well recognized that there are well-performing tests and some that do not perform so well, yet they are all called RASTs, making it difficult to distinguish which is which. For these reasons, it is now recommended that use of RAST as a generic descriptor of these tests be abandoned.[17]

The updated version, the ImmunoCAP Specific IgE blood test, is the only specific IgE assay to receive Food and Drug Administration approval to quantitatively report to its detection limit of 0.1kU/L.[162]

Medical specialty

[edit]
Allergist/Immunologist
Occupation
Names
  • Physician
Occupation type
Specialty
Activity sectors
Medicine
Specialtyimmunology
Description
Education required
Fields of
employment
Hospitals, Clinics

The medical speciality that studies, diagnoses and treats diseases caused by allergies is called allergology.[163] An allergist is a physician specially trained to manage and treat allergies, asthma, and the other allergic diseases. In the United States physicians holding certification by the American Board of Allergy and Immunology (ABAI) have successfully completed an accredited educational program and evaluation process, including a proctored examination to demonstrate knowledge, skills, and experience in patient care in allergy and immunology.[164] Becoming an allergist/immunologist requires completion of at least nine years of training.

After completing medical school and graduating with a medical degree, a physician will undergo three years of training in internal medicine (to become an internist) or pediatrics (to become a pediatrician). Once physicians have finished training in one of these specialties, they must pass the exam of either the American Board of Pediatrics (ABP), the American Osteopathic Board of Pediatrics (AOBP), the American Board of Internal Medicine (ABIM), or the American Osteopathic Board of Internal Medicine (AOBIM). Internists or pediatricians wishing to focus on the sub-specialty of allergy-immunology then complete at least an additional two years of study, called a fellowship, in an allergy/immunology training program. Allergist/immunologists listed as ABAI-certified have successfully passed the certifying examination of the ABAI following their fellowship.[165]

In the United Kingdom, allergy is a subspecialty of general medicine or pediatrics. After obtaining postgraduate exams (MRCP or MRCPCH), a doctor works for several years as a specialist registrar before qualifying for the General Medical Council specialist register. Allergy services may also be delivered by immunologists. A 2003 Royal College of Physicians report presented a case for improvement of what were felt to be inadequate allergy services in the UK.[166]

In 2006, the House of Lords convened a subcommittee. It concluded likewise in 2007 that allergy services were insufficient to deal with what the Lords referred to as an "allergy epidemic" and its social cost; it made several recommendations.[167]

Research

[edit]

Low-allergen foods are being developed, as are improvements in skin prick test predictions; evaluation of the atopy patch test, wasp sting outcomes predictions, a rapidly disintegrating epinephrine tablet, and anti-IL-5 for eosinophilic diseases.[168]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
An allergy is a disorder in which the produces an exaggerated response to ordinarily harmless environmental substances known as , potentially leading to a range of symptoms from mild discomfort to life-threatening reactions. This response is primarily mediated by (IgE) antibodies, which, upon re-exposure to the , bind to mast cells and basophils, triggering the release of inflammatory mediators such as that cause , increased vascular permeability, and contraction. Common include airborne particles like , dust mites, and pet dander; foods such as , , and ; insect stings; medications like penicillin; and materials like . Symptoms of allergies depend on the and the affected body system but frequently involve the (sneezing, runny or stuffy nose, coughing, wheezing), (itching, , eczema), eyes (itching, redness, watering), and (, , ), with severe cases manifesting as —a rapid, systemic reaction that can include throat swelling, difficulty breathing, a drop in , and shock. Allergies affect approximately 20–30% of the global population, with alone impacting 10–30% worldwide, and prevalence rates have been rising, particularly in industrialized nations due to factors like and changes in practices. Risk factors include a family history of allergies or , atopic conditions in infancy, and environmental exposures, with playing a key role in susceptibility. Complications can include chronic , exacerbation, recurrent infections, and fatal if untreated. Diagnosis typically involves a detailed , , skin prick tests, blood tests for specific IgE, and sometimes oral food challenges, while management strategies emphasize allergen avoidance, pharmacological interventions like antihistamines, decongestants, corticosteroids, and epinephrine auto-injectors for emergencies, as well as (such as subcutaneous injections or sublingual tablets) to induce tolerance over time.

Overview

Definition and Classification

An allergy is defined as a reaction initiated by immunologic mechanisms, typically involving an exaggerated to otherwise harmless environmental substances known as allergens. This response is most commonly associated with , an immediate reaction mediated by (IgE) antibodies, where allergens bind to IgE on the surface of mast cells and , triggering the release of inflammatory mediators such as . While allergies are primarily type I, the broader category of includes types II (antibody-dependent ), III (immune complex-mediated), and IV (T-cell-mediated delayed reactions), which can overlap with certain allergic-like conditions but differ in their immune pathways. The Gell and Coombs classification system, established in 1963, categorizes reactions into four types based on the underlying immune mechanisms, with type I being the predominant form in classical allergies. In type I reactions, sensitization occurs upon initial allergen exposure, leading to IgE production; subsequent exposures cause rapid degranulation of effector cells, resulting in immediate symptoms such as , a severe systemic response involving multiple organs. This classification remains foundational in , distinguishing type I from non-IgE-mediated hypersensitivities like type IV . Allergies are further classified as atopic or non-atopic, with atopic allergies representing IgE-mediated conditions driven by a , while non-atopic allergies involve non-IgE mechanisms such as direct activation or T-cell responses. The World Health Organization's () organizes allergic disorders into categories like respiratory (e.g., ), skin (e.g., ), and multisystem (e.g., ), emphasizing improved grouping under conditions to reflect immunologic distinctions, including atopic and non-atopic forms. Atopy refers to the hereditary tendency to develop IgE-mediated to common allergens, characterized by elevated IgE levels and Th2-biased immune responses, often manifesting in conditions like or . The process, a prerequisite for allergic reactions, begins when allergens breach epithelial barriers, are processed by dendritic cells, and promote Th2 cell differentiation, leading to B-cell production of allergen-specific IgE that binds to high-affinity receptors on mast cells. This initial phase establishes long-term sensitivity, enabling rapid responses upon re-exposure.

Common Types

Allergies manifest in various forms, with the most common types including , , , food allergies, drug allergies, insect sting allergies, and . These conditions are primarily mediated by (IgE) antibodies and affect approximately 100 million people , contributing to substantial healthcare burdens. , commonly known as hay fever, involves of the nasal passages due to inhaled allergens and is one of the most prevalent allergic conditions, affecting 10% to 30% of the population worldwide. In the , approximately 25.7% of adults report a diagnosed seasonal allergy, often overlapping with allergic rhinitis. It is characterized by chronic or seasonal episodes triggered by environmental factors like . Asthma, particularly allergic asthma, is a chronic respiratory condition where airway and hyperresponsiveness lead to recurrent episodes of wheezing and . Allergic asthma accounts for the majority of cases, comprising 60% to 80% of in children and a substantial proportion in adults. Overall asthma prevalence in the is about 8.6% among adults and 5.8% among children, with allergic triggers playing a dominant role. Atopic dermatitis, or eczema, is a chronic inflammatory disorder often beginning in childhood and linked to a defective barrier that allows penetration. It affects approximately 11% of the population and 5% to 20% of children globally. This type is frequently associated with other atopic conditions, forming part of the "atopic march." Food allergies arise from IgE-mediated immune responses to ingested proteins, potentially leading to rapid-onset reactions. In the , diagnosed prevalence is 6.2% among adults and 5.8% among children. Common triggers include the top nine major allergens identified by the FDA: , eggs, , crustacean , tree nuts, , , soybeans, and , with (2.9%), (1.9%), and (1.8%) being among the most frequent. Drug allergies involve hypersensitivity reactions to medications, most commonly antibiotics like penicillin, and can range from mild to severe. Self-reported prevalence in the is around 10% in the general population, though confirmed IgE-mediated cases are lower, at 1% to 2%. These allergies often result from repeated exposure and are more common in healthcare settings. Insect sting allergies occur due to from insects like bees and wasps, leading to systemic reactions in susceptible individuals. The prevalence of systemic allergic reactions is estimated at 0.5% to 3% in the , with about 1% of children and 3% of adults affected. Large local reactions are more common, affecting up to 26% of the population. Latex allergy is an IgE-mediated response to proteins in , historically prevalent among healthcare workers due to occupational exposure. In the general population, prevalence ranges from 1% to 6%, though rates have declined with reduced use in medical products. Allergic reactions can be classified as systemic or localized based on their scope. Systemic allergies, exemplified by , involve widespread physiological effects across multiple organ systems and pose immediate life-threatening risks, often triggered by foods, drugs, or stings. In contrast, localized allergies, such as urticaria (), are confined primarily to the skin and result in transient itchy welts without broader involvement. An emerging type is oral allergy syndrome (OAS), linked to between allergens and structurally similar proteins in certain raw fruits, , and nuts. It affects 13% to 58% of adults with allergies, though overall population prevalence is lower, around 4.7% to 20% in children with allergic diseases. This condition highlights the role of genetic predispositions in enhancing susceptibility to cross-reactive allergies.

Clinical Presentation

General Signs and Symptoms

Allergic reactions commonly manifest with a range of general symptoms that can affect multiple body systems, including itching known as pruritus, sneezing, runny nose or rhinorrhea, watery eyes, swelling referred to as angioedema, hives or urticaria, and wheezing. These symptoms arise due to the release of inflammatory mediators following allergen exposure and are often the first indicators of an allergic response. The onset and progression of these symptoms vary by reaction type, with immediate responses typically occurring within minutes of exposure, while delayed reactions may develop over hours. Immediate symptoms, such as sudden sneezing or , reflect rapid activation of the allergic cascade, whereas delayed manifestations like prolonged swelling can persist or intensify later. In severe cases, allergic reactions can escalate to systemic involvement, culminating in , a life-threatening condition characterized by widespread symptoms including severe wheezing, extensive , and cardiovascular instability. Cutaneous manifestations are absent in 10–20% of cases, particularly in severe reactions. may exhibit a biphasic response, where symptoms recur typically within 1 to 72 hours after the initial episode resolves (often 1–48 hours), even without further allergen exposure, necessitating prolonged observation. Severity is often graded using the Ring and Messmer classification, which ranges from Grade I (mild mucocutaneous symptoms like localized ) to Grade IV (severe cardiovascular or ). Beyond acute effects, general allergic symptoms significantly impair , particularly through nocturnal disruptions such as persistent or itching that lead to fragmented and daytime . These sleep disturbances exacerbate overall morbidity, contributing to reduced productivity and emotional distress in affected individuals.

Organ-Specific Manifestations

Allergic reactions frequently manifest in the , where they can affect both the upper and lower airways. In the upper , presents with symptoms such as , sneezing, , and nasal itching, often triggered by airborne allergens like or dust mites. In the lower airways, involves leading to wheezing, , , and chest tightness, resulting from airway and hyperresponsiveness. Skin manifestations of allergy commonly include , or eczema, characterized by recurrent flares of intensely itchy, red, and inflamed skin patches, particularly on the face, elbows, and knees in children. , in contrast, produces localized patterns of rash, such as linear streaks or geometric shapes corresponding to the contact site, with symptoms including redness, vesicles, and oozing upon exposure to allergens like or fragrances. Gastrointestinal involvement is prominent in food allergies, where ingestion of the allergen can cause immediate symptoms like , abdominal cramping, and due to mast cell in the gut mucosa. These reactions may also lead to and , reflecting localized and altered gut motility. Ocular allergies often take the form of , featuring intense itching, redness, tearing, and of the , typically bilateral and associated with environmental allergens. swelling, or periorbital , frequently accompanies these symptoms, exacerbating discomfort and sometimes impairing vision. Systemic manifestations occur in severe cases like , where widespread activation leads to , , and , compromising multiple organs including the cardiovascular and respiratory systems. This can result in rapid progression to loss of consciousness if untreated. Rare manifestations include (ABPA), a reaction to in the lungs of asthmatic individuals, presenting with productive cough, wheezing, dyspnea, and expectoration of brownish mucus plugs containing fungal hyphae. ABPA may also cause low-grade fever and in advanced stages.

Etiology

Allergens and Triggers

Allergens are substances that provoke an in sensitized individuals, leading to allergic reactions. These triggers vary by exposure route and include environmental, dietary, and occupational agents. Common categories encompass inhalant, ingestant, injectable, and occupational allergens, each associated with specific proteins or components that elicit IgE-mediated responses. Inhalant allergens primarily affect the and are airborne particles inhaled into the lungs or nasal passages. from such as and grasses represents a major group, with causing seasonal in late summer and fall, while grass peaks in spring and summer. mites, particularly of Dermatophagoides like D. pteronyssinus and D. farinae, thrive in and bedding, releasing fecal particles and body fragments that serve as potent aeroallergens. Mold spores from fungi such as and disperse indoors and outdoors, exacerbating allergies in damp environments. Pet dander, consisting of skin flakes, saliva, and urine proteins from cats () and dogs (Can f 1), persists in the air and on surfaces, triggering perennial symptoms. Ingestant allergens are consumed through food and provoke gastrointestinal or systemic reactions upon digestion. The most prevalent include the "Big 9" major food allergens: milk (casein and whey proteins), eggs (ovalbumin), (Ara h proteins), tree nuts (such as almonds and walnuts), soy (Gly m proteins), (gliadins), (parvalbumins), (tropomyosin), and (2S albumins). These account for approximately 90% of food allergy reactions in the United States. Injectable allergens enter via stings, injections, or infusions, potentially causing rapid systemic responses like . Insect venoms from such as bees (Apis mellifera) and wasps (Vespula species) contain and , with clinical allergy affecting 0.3–7.5% of adults. Certain medications, including beta-lactam antibiotics like penicillins, can trigger IgE-mediated reactions through side-chain similarities, while non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen often cause non-IgE-mediated via direct activation or altered metabolism. Occupational allergens arise in work environments, with exemplifying a key trigger in the industry. proteins, including alpha-amylase inhibitors and gliadins, cause , a form of occupational airway affecting up to 10% of exposed bakers through chronic inhalation. occurs when structurally similar proteins in unrelated allergens provoke reactions due to shared epitopes. A classic example is between (Bet v 1) and apples (Mal d 1), leading to where individuals experience oral itching upon consuming raw apples, though cooking denatures the allergen. Genetic factors may influence susceptibility to these triggers, but external exposure remains the primary initiator.

Genetic and Immunological Predispositions

Allergies have a significant genetic component, with heritability estimates for ranging from 50% to 80% based on twin and family studies. Specific genetic variants, such as loss-of-function mutations in the gene (FLG), predispose individuals to atopic eczema by impairing skin barrier function and increasing susceptibility to penetration. Similarly, certain (HLA) alleles, including HLA-B57:01 and HLA-B15:02, are strongly associated with idiosyncratic drug hypersensitivity reactions, conferring odds ratios as high as 100 or more for specific drug- pairs. Family history serves as a key , evidenced by twin studies showing higher concordance rates in monozygotic pairs compared to dizygotic pairs; for instance, monozygotic twins exhibit a sixfold increased of relative to dizygotic twins' threefold , highlighting shared genetic influences on allergic predisposition. This familial aggregation underscores the polygenic nature of allergy , where multiple loci contribute to overall susceptibility. The atopic march describes the sequential progression of allergic diseases, often beginning with infantile eczema, advancing to food allergies in early childhood, and culminating in or later in life, driven by underlying genetic vulnerabilities that amplify s to environmental exposures. Immunologically, predispositions involve a Th2-skewed adaptive , characterized by elevated production of cytokines such as IL-4, IL-5, and IL-13, which promote IgE class switching and recruitment in susceptible individuals. Deficiencies in regulatory T cells (Tregs), which normally suppress aberrant Th2 activation and maintain , further exacerbate this imbalance, leading to unchecked allergic inflammation. Epigenetic modifications, including DNA methylation patterns at loci regulating IgE production, also contribute to allergy risk by altering without changing the DNA sequence; for example, hypomethylation at specific CpG sites in immune cells correlates with higher serum IgE levels and atopic sensitization. These heritable yet environmentally influenced marks help explain variability in disease onset and severity among genetically predisposed individuals.

Pathophysiology

Acute Allergic Response

The acute allergic response, a hallmark of , begins when an encounters IgE antibodies bound to the high-affinity FcεRI receptors on the surface of sensitized mast cells and . This interaction causes cross-linking of adjacent IgE molecules, activating tyrosine kinases such as Lyn and Syk within the cells, which initiate a signaling cascade involving , calcium influx, and activation. The result is rapid , typically occurring within seconds to minutes of exposure. Degranulation leads to the immediate release of preformed mediators from intracellular granules, primarily , along with proteases and cytokines, followed by the and of lipid mediators such as (e.g., LTC4, LTD4) and (e.g., PGD2). exerts its effects by binding to H1 receptors on vascular endothelial cells, causing and increased permeability that results in and ; it also stimulates H1 receptors on bronchial , inducing and . and amplify these responses by promoting sustained , , and further vascular leakage through their actions on cysteinyl leukotriene receptors (CysLT1) and prostaglandin receptors, respectively. The overall cascade—from allergen-IgE cross-linking to mediator release—produces the characteristic rapid-onset symptoms of acute allergy, including localized or systemic effects like urticaria, , , and wheezing, which peak within 5–30 minutes. In sensitized individuals, even trace amounts of can trigger this response due to the high sensitivity of FcεRI-bound IgE. When the acute response becomes systemic and severe, it manifests as , a potentially fatal condition involving massive mediator release from multiple and populations. This leads to widespread , profound , and cardiovascular collapse, primarily through histamine-mediated reductions in systemic and venous return, compounded by leukotriene-induced cardiac depression and fluid into tissues. Biphasic cardiovascular effects may occur, with initial giving way to and arrest if untreated, underscoring the need for immediate epinephrine administration to counteract these mechanisms.

Late-Phase Response and Chronic Effects

The late-phase response in allergic reactions occurs 4 to 8 hours after initial exposure and involves the recruitment of inflammatory cells such as , neutrophils, and T cells to the affected tissues. This recruitment is mediated by chemotactic factors released during the early phase, leading to sustained inflammation in the airways, skin, or mucosa. In asthmatic individuals, fluid shows increased numbers of and neutrophils as early as 4 hours post-challenge, correlating with the severity of the response and heightened airway sensitivity to stimuli like . T lymphocytes, particularly + helper T cells, further amplify this process by releasing lymphokines that enhance activation and survival. Cytokines produced by Th2 cells play a central role in sustaining the late-phase inflammation, with interleukin-4 (IL-4), IL-5, and IL-13 being key mediators. IL-5 promotes recruitment and activation, while IL-4 and IL-13 drive production, IgE synthesis, and ongoing tissue inflammation. In nasal allergen challenges, elevations in IL-5 and IL-13 protein levels are observed in the late phase among responders, alongside IL-1β, indicating a type 2 inflammatory profile that perpetuates symptoms like congestion and obstruction. These cytokines are secreted predominantly by memory Th2 cells, which dominate the cellular infiltrate in late-phase reactions across various allergic diseases. Over time, repeated late-phase responses contribute to chronic structural changes in allergic diseases. In asthma, persistent leads to airway remodeling, characterized by hypertrophy, subepithelial , and , which exacerbate airflow limitation and disease severity. IL-13, in particular, drives these remodeling processes by stimulating epithelial and deposition in the airway wall. Mast cells infiltrating the airway release mediators that further promote this remodeling, linking late-phase events to long-term . In the skin, chronic allergic manifests as , particularly in conditions like , where late-phase responses result in dermal thickening and accumulation in lichenified lesions. This is driven by Th2 s and eosinophil-derived factors that activate fibroblasts, leading to persistent tissue stiffness and impaired . The late-phase response significantly contributes to disease progression, as seen in persistent , where ongoing airway sustains hyperresponsiveness and exacerbations even after acute symptoms resolve. Corticosteroids effectively target this inflammatory persistence by inhibiting late-phase cell recruitment and release, underscoring the need for strategies to prevent chronicity. In both and , unchecked late-phase mechanisms transform episodic reactions into enduring pathological states, highlighting their role in long-term morbidity.

Diagnostic Approaches

In Vivo Testing

In vivo testing encompasses diagnostic methods that directly assess allergic responses in living patients by introducing potential allergens or triggers and observing physiological reactions, providing insights into immediate or delayed . These tests are particularly valuable for confirming clinical suspicion when history and results are inconclusive, as they mimic real-world exposure under controlled conditions. Skin prick testing (SPT) is a widely used first-line method for detecting IgE-mediated allergies to inhalants, foods, and venoms. The procedure involves placing a drop of extract on the patient's or back, followed by a shallow prick with a lancet to introduce the into the without drawing blood; serves as a positive control and saline as a negative control. Results are read after 15-20 minutes, with a positive reaction defined as a wheal diameter of at least 3 mm larger than the negative control, indicating . Common allergens tested include pollens, dust mites, pet , and foods like or . SPT is advantageous due to its rapidity (results in under 30 minutes), low cost, and safety profile, though it may yield false positives in highly atopic individuals. Intradermal testing () builds on SPT for s with lower sensitivity, such as certain drugs, insect s, or antibiotics, by injecting a diluted solution (typically 1:1000 to 1:100 of the SPT concentration) into the of the . This method produces a more pronounced response due to deeper delivery, with positivity determined by a wheal at least 3 mm larger than the negative control after 15-20 minutes. is more sensitive than SPT but carries a higher of systemic reactions, necessitating epinephrine availability and use primarily when SPT is negative but suspicion remains high. Guidelines from allergy societies recommend for evaluating penicillin or allergies after negative SPT. Patch testing evaluates type IV delayed reactions, commonly associated with from metals, fragrances, or preservatives. Standardized allergens in petrolatum are applied to patches on the patient's back and secured with , remaining in place for 48 hours to allow penetration into the . Readings occur at 48 hours (D2) for early reactions and 72-96 hours (D3-D4) post-application, grading responses as positive if erythematous papules, vesicles, or bullae form, indicating T-cell mediated allergy. This test is essential for occupational or cosmetic-related allergies but requires patient avoidance of showers and irritants during the period. European and American guidelines emphasize baseline series testing with 35-70 allergens for comprehensive evaluation. The double-blind placebo-controlled food challenge (DBPCFC) serves as the gold standard for confirming IgE- or non-IgE-mediated food allergies when or tests are equivocal. Conducted in a supervised setting, the patient ingests escalating doses of the suspected food (e.g., or ) disguised in opaque capsules or mixed into vehicles, alternated with on separate days to blind both patient and observer; challenges proceed until a cumulative dose equivalent to a typical serving or a reaction occurs. Monitoring includes and symptom observation for up to 2 hours post-dose, with epinephrine ready for . DBPCFC minimizes bias but is time-intensive and risky, reserved for ambiguous cases per international guidelines. Exercise or cold-induced challenges diagnose physical urticarias or triggered by specific stimuli. For , patients or cycle to 85% maximum for 15-30 minutes while monitored for , wheezing, or , sometimes combined with food intake if suspected. is assessed via an ice cube test, applying ice to the for 5 minutes and observing wheal formation within 10 minutes post-removal. These provocation tests confirm trigger specificity and guide avoidance, with protocols outlined in urticaria management guidelines to ensure safety.

In Vitro and Other Methods

In vitro diagnostic methods for allergies involve laboratory analyses of blood or other samples to detect immune responses without directly exposing the patient to allergens, providing a safer alternative to testing such as skin prick tests. These approaches primarily measure (IgE) antibodies and cellular responses associated with allergic sensitization. Blood tests are the cornerstone of allergy diagnostics, focusing on serum-specific IgE levels to identify to particular . The (RAST), an early method using radiolabeled anti-IgE antibodies, detects allergen-specific IgE in serum but has largely been supplanted by more sensitive assays like ImmunoCAP, which employs for quantitative measurement of specific IgE against extracts or components from over 500 . ImmunoCAP is considered the gold standard due to its high reproducibility and correlation with clinical symptoms, with results reported in kUA/L units where levels above 0.35 kUA/L indicate positivity. Total IgE testing complements specific IgE assays by quantifying overall IgE in serum, with elevated levels (typically >100 kU/L in adults) suggesting , though it lacks specificity for individual and can be influenced by non-allergic conditions like parasitic infections. Component-resolved diagnostics (CRD) enhances precision by assessing IgE reactivity to individual allergen molecules, such as Ara h 2 for , enabling risk stratification and differentiation between primary and cross-reactive sensitizations. The activation test () offers a functional cellular assessment of allergy by measuring in samples stimulated with allergens. Using , quantifies upregulation of activation markers like on surfaces, with percentage activation above 15% often indicating clinical relevance; it is particularly useful for diagnosing and allergies where testing is inconclusive. Compared to specific IgE tests, provides higher specificity (up to 96% for certain allergens) by reflecting the allergenic potency rather than mere . Other in vitro and minimally invasive methods support allergy diagnosis in specific contexts. evaluates pulmonary function to confirm allergic , measuring forced expiratory volume in one second (FEV1) and the FEV1/ , with reversible obstruction (≥12% improvement post-bronchodilator) indicating an allergic component. Nasal provocation testing, involving controlled delivery to the followed by symptom scoring or peak nasal inspiratory flow measurement, confirms inhalant allergies like when serological tests are equivocal. with is essential for diagnosing (EoE), an allergy-related condition, where esophageal tissue shows ≥15 per , often revealing endoscopic features like rings or furrows. Genetic testing identifies predispositions that may mimic or exacerbate allergic conditions, such as alpha-1 antitrypsin deficiency (AATD), a SERPINA1 gene variant causing low AAT levels and lung inflammation resembling allergic asthma. Blood-based genotyping detects common alleles like PIZ and PIS, aiding differentiation from true IgE-mediated allergies. Despite their utility, in vitro methods have limitations including false positives from cross-reactivity (e.g., up to 50% in broad food panels) and false negatives in early or mild sensitization, reducing diagnostic accuracy to 70-90% compared to provocation challenges. High costs, particularly for multiplex CRD or BAT (often $200-500 per test), restrict accessibility, though they may lower overall healthcare expenses by reducing unnecessary specialist visits.

Prevention Strategies

Primary Prevention Measures

Primary prevention of allergies focuses on interventions aimed at reducing the incidence of allergic and disease onset in susceptible individuals, particularly infants at high risk due to family history. Key strategies include targeted modifications to early-life exposures and nutritional practices, informed by clinical trials and epidemiological evidence. Regarding the timing of allergen introduction, traditional guidelines once recommended delayed exposure to common food like for high-risk infants to prevent . However, the Learning Early About Peanut Allergy (LEAP) study, a involving 640 infants with severe eczema and/or , demonstrated that early introduction of peanut products between 4 and 11 months of age reduced the prevalence of by 81% at age 5 years compared to avoidance. Recent U.S. studies as of 2025 indicate a 27% reduction in peanut allergy incidence and up to 38% in overall food allergies following guideline adoption. This finding prompted updated guidelines from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID), recommending early peanut introduction for high-risk infants after assessment, shifting away from strict avoidance to promote tolerance development. Breastfeeding is promoted as a protective measure against allergy development, with evidence indicating that exclusive for at least 4 months may lower the risk of in infants. Evidence on breastfeeding's protective effect against IgE-mediated food allergies is mixed; some reviews suggest reduced risk of atopic diseases, while recent meta-analyses show no clear benefit or slight increase for food allergies. A of cohort studies found that breastfed infants had reduced odds of developing compared to formula-fed peers, potentially due to immunomodulatory factors in such as transforming growth factor-beta. Concurrently, maternal diet during and should emphasize a varied, nutrient-rich without restrictive allergen avoidance, as meta-analyses show no benefit from eliminating foods like or , and such restrictions may even increase risk. Guidelines from the British Society for Allergy and Clinical Immunology (BSACI) endorse a balanced diet including fruits, , and proteins to support fetal immune maturation. Environmental controls in early life target indoor allergens to mitigate risks. For house dust mites (HDM), a major respiratory , measures such as using allergen-proof and encasings, maintaining indoor below 50%, and regular washing of bedding in hot water have been shown to reduce HDM exposure by up to 90%, with some trials showing reduced to HDM but limited evidence for lowering incidence of and in high-risk children. In contrast, early exposure to pets aligns with critiques of the , which posits that reduced microbial diversity in modern environments contributes to allergy rises; studies indicate that or ownership in the first year of life decreases allergy risk in a dose-dependent manner, with households having two or more pets associated with 20-30% lower odds of to pet allergens and overall . Modulation of the gut microbiome through and prebiotics represents an emerging strategy for preventing atopic diseases. Meta-analyses of randomized controlled trials demonstrate that prenatal and postnatal supplementation with specific strains, such as Lactobacillus rhamnosus GG, reduces the risk of eczema in high-risk infants by 20-30%, with stronger effects when combined with prebiotics like galacto-oligosaccharides that promote beneficial bacteria growth. These interventions influence immune balance by enhancing regulatory T-cell activity and reducing Th2 responses, though evidence for preventing food allergies or remains moderate and strain-specific. The World Allergy Organization recommends targeted use in at-risk populations based on these findings. Public health policies, including mandatory allergen labeling laws, support primary prevention by fostering informed dietary choices and reducing unintended exposures that could trigger sensitization. The U.S. Food Allergen Labeling and Consumer Protection Act (FALCPA) of 2004 requires clear declaration of eight major s on packaged foods, which has increased consumer awareness and decreased accidental ingestion rates, with one study estimating a 24% reduction in adults. Similar regulations in the under Regulation (EU) No 1169/2011 emphasize bold labeling, contributing to reduced allergy-related healthcare burdens.

Secondary Prevention and Risk Reduction

Secondary prevention in allergies focuses on strategies to mitigate episodes and halt disease progression in individuals who have already developed to allergens, thereby reducing symptom severity and complications without aiming for . These approaches emphasize environmental control, prophylactic , and behavioral modifications tailored to the patient's specific triggers. By intervening after sensitization but before severe manifestations, such measures can interrupt the cascade of allergic responses and improve . Allergen avoidance remains a cornerstone of secondary prevention, particularly for indoor and outdoor triggers in sensitized patients. For house dust mite allergy, which affects many with asthma and rhinitis, encasing mattresses, pillows, and box springs in mite-impermeable covers with pore sizes less than 10 micrometers significantly reduces exposure to allergens like Der p 1, leading to decreased symptom scores in multifaceted interventions. Complementing this, maintaining indoor relative humidity between 35% and 50% using dehumidifiers inhibits mite proliferation, while regular vacuuming with HEPA-filtered vacuums removes allergen-laden particles, though standalone HEPA air purifiers show more limited benefits unless combined with other controls. For pollen-sensitized individuals, closing windows during high pollen seasons and using HEPA filters in air conditioning units can lower airborne allergen levels and prevent exacerbations. Pre-exposure allergen immunotherapy, such as sublingual administration before seasonal peaks, further enhances tolerance in sensitized patients, reducing the risk of acute reactions upon unavoidable exposure. Prophylactic medications play a key role in preempting allergic episodes for those with known triggers. Intranasal corticosteroids, recommended as first-line therapy for persistent in sensitized adults and children, effectively suppress nasal when initiated 2-4 weeks before anticipated exposure, outperforming oral antihistamines in reducing symptoms like congestion and sneezing. Oral or intranasal antihistamines, taken prophylactically before predictable triggers such as pet exposure or , provide rapid symptom relief and are particularly useful as adjuncts to corticosteroids in moderate cases. These agents are well-tolerated long-term, with intranasal formulations minimizing systemic effects. Lifestyle modifications are essential for managing and allergies in sensitized individuals, focusing on vigilant avoidance to prevent . For allergies, strict dietary elimination of confirmed allergens, guided by allergy testing and input, is critical, as inadvertent exposure can trigger severe reactions; on label reading and cross-contamination risks forms the basis of long-term risk reduction. In allergy following a sting reaction, avoidance behaviors—such as wearing protective clothing outdoors, avoiding scented products, and steering clear of areas with high activity—significantly lower re-exposure chances, with epinephrine auto-injectors carried at all times for emergencies. Monitoring the atopic march enables early intervention to curb progression from initial , such as , to later conditions like or . In children with early-onset eczema, regular assessment of sensitization markers and symptom evolution identifies high-risk trajectories, allowing timely introduction of moisturizers, topical anti-inflammatories, or allergen-specific strategies to break the progression chain, with studies showing up to 25% of cases advancing if unchecked. Additionally, vaccinations against respiratory co-infections, like annual , prevent exacerbations in sensitized asthmatic patients by reducing infection-triggered attacks by 59%-78%, as evidenced in systematic reviews of vaccinated cohorts.

Treatment and Management

Pharmacological Interventions

Pharmacological interventions for allergies primarily target the relief of symptoms and the control of inflammation associated with allergic reactions, ranging from mild to severe . These treatments include a variety of drug classes that modulate key mediators such as , leukotrienes, and IgE, providing symptomatic relief without altering the underlying . Selection of therapy depends on the type and severity of the allergic condition, with oral, topical, inhaled, or injectable formulations commonly used. Antihistamines, particularly H1-receptor antagonists, are first-line agents for managing mild-to-moderate allergic symptoms such as sneezing, itching, , and urticaria. These medications work by competitively blocking at H1 receptors on effector cells, thereby inhibiting downstream effects like and contraction; second-generation options like loratadine and are preferred due to their non-sedating profiles and rapid onset. Loratadine, for example, provides 24-hour relief with minimal penetration, while offers effective symptom control but may cause mild drowsiness in about 10% of users. They are available over-the-counter and are recommended as monotherapy for intermittent or in combination with other agents for persistent cases. Corticosteroids suppress allergic by binding to receptors, leading to reduced production of pro-inflammatory cytokines and inhibition of immune cell migration. Intranasal formulations like fluticasone are highly effective for , improving nasal congestion and obstruction with once-daily dosing, while inhaled versions such as fluticasone propionate control symptoms by targeting airway . Topical corticosteroids, including cream, are used for allergies like eczema, providing localized without significant systemic absorption. Systemic corticosteroids like are reserved for severe exacerbations, such as acute flares, due to risks like with prolonged use; short courses (up to 5 days) are preferred for safety. Intranasal corticosteroids are considered first-line or alternative therapy for moderate-to-severe per consensus guidelines. Decongestants offer rapid relief from nasal and sinus congestion by stimulating alpha-adrenergic receptors, causing and reduced mucosal swelling. Oral is commonly used for systemic effects in , while topical nasal sprays provide quick onset but are limited to short-term use (less than 3 days) to avoid rebound congestion or . They are adjunctive for severe nasal obstruction but contraindicated in patients with or due to potential elevation. Leukotriene modifiers, such as , inhibit the action of cysteinyl leukotrienes—potent inflammatory mediators released from mast cells and —thereby reducing , mucus production, and in allergic and . is administered orally once daily and is particularly useful as add-on therapy for patients with concomitant , showing moderate efficacy in alleviating nasal symptoms, though less potent than intranasal corticosteroids. It requires a prescription and carries warnings for neuropsychiatric side effects like mood changes. Mast cell stabilizers like cromolyn sodium prevent the of s and , thereby blocking the release of and other mediators that trigger early-phase allergic responses. Available as nasal sprays or , cromolyn is effective for mild or but requires regular use (up to 4 times daily) for several days to achieve full prophylactic benefit. It is generally well-tolerated with few side effects and is a safe option for pregnant individuals or those intolerant to other therapies. For life-threatening , epinephrine auto-injectors such as EpiPen are the first-line emergency treatment, rapidly reversing , , and airway by activating alpha- and beta-adrenergic receptors to promote , bronchodilation, and cardiac stimulation. The standard adult dose is 0.3 mg intramuscularly into the anterolateral , with a pediatric dose of 0.15 mg for children weighing 15-30 kg; a second dose may be given after 5-15 minutes if symptoms persist, and patients at risk should carry two injectors at all times. Immediate administration is critical, followed by emergency medical care, as epinephrine does not replace the need for professional intervention. Biologics like represent for severe allergic diseases, functioning as a humanized that binds free IgE, preventing its interaction with high-affinity receptors on mast cells and , thus downregulating IgE-mediated inflammation and reducing recruitment. is indicated as add-on maintenance for moderate-to-severe persistent allergic inadequately controlled by inhaled corticosteroids, administered subcutaneously every 2-4 weeks based on serum IgE and body weight. It has also shown efficacy in refractory to antihistamines and is approved by the FDA (as of February 2024) for reducing risk from accidental food allergen exposure in IgE-mediated food allergies. Use is limited to specialist settings due to cost and monitoring requirements for rare anaphylactic risks. Targeted therapies such as remibrutinib (Rhapsido), a inhibitor (BTKi), were approved by the FDA in September 2025 for (CSU) in adults and adolescents aged 12 years and older refractory to H1-antihistamines. Remibrutinib inhibits BTK to reduce and activation, providing rapid and sustained relief from itching and with oral dosing of 50 mg twice daily. Clinical trials demonstrated significant improvements in urticaria activity scores as early as week 1, with a favorable profile.

Immunotherapy and Desensitization

, also known as desensitization, represents a for allergies that aims to induce long-term tolerance to specific by gradually exposing the to increasing doses of the allergen. Unlike symptomatic treatments, it addresses the underlying , potentially reducing or eliminating allergic reactions over time. This approach is particularly effective for IgE-mediated allergies such as , , food allergies, and insect venom . Subcutaneous immunotherapy (SCIT), administered via injections of extracts, is a standard treatment for respiratory allergies like and . The process involves two phases: a build-up phase with frequent injections of escalating doses over several weeks to months, followed by a maintenance phase with regular injections every 4-6 weeks for 3-5 years to sustain tolerance. Clinical studies have shown SCIT efficacy in reducing symptoms and medication use by 70-80% in patients with and , with benefits persisting post-treatment. Sublingual immunotherapy (SLIT) delivers allergens through tablets or drops placed under the , offering a convenient alternative to injections for and certain allergies. SLIT is approved for grass, , dust mite, and tree allergies, with treatment typically involving daily dosing for 3 years, starting with an initial escalation. It has demonstrated efficacy in reducing seasonal symptoms and medication needs by approximately 30-40%, alongside a favorable safety profile characterized by mostly mild local reactions like oral itching, with systemic reactions rare (less than 1%). For allergies, SLIT shows promise in desensitizing patients to allergens like or , though it is less potent than oral routes and primarily used off-label. Oral (OIT) focuses on allergies, involving progressive ingestion of under medical supervision to build tolerance. For , Palforzia (AR101), an FDA-approved OIT product since 2020, uses encapsulated protein powder in initial dose escalation, up-dosing, and maintenance phases, enabling patients aged 4-17 to tolerate higher amounts and reduce reaction severity. Clinical trials confirmed its efficacy in desensitizing about 67% of participants to a 600 mg protein challenge, though ongoing daily dosing is required for sustained benefit. Venom immunotherapy (VIT) is highly effective for preventing anaphylaxis from Hymenoptera (bee and wasp) stings in sensitized individuals. Administered subcutaneously with purified venom extracts over 3-5 years, it significantly reduces the risk of systemic reactions by up to 90% upon re-stinging, with protection lasting years after discontinuation in most cases. The mechanisms underlying these immunotherapies involve inducing immune tolerance through modulation of T-cell responses. Allergen exposure promotes the generation of regulatory T-cells (Tregs), particularly Foxp3+ Tregs, which suppress Th2-dominated allergic inflammation by producing anti-inflammatory cytokines like IL-10 and TGF-β. Concurrently, there is a shift toward a Th1 response, increasing IFN-γ production to counterbalance Th2 cytokines (IL-4, IL-5, IL-13), alongside reduced IgE and elevated IgG4 antibodies that block allergen-IgE interactions. These changes lead to sustained peripheral tolerance, preventing allergic effector cell activation.

Epidemiology

Global Prevalence and Distribution

Allergic diseases represent a major burden, affecting an estimated 20-30% of the world's . Allergic rhinitis alone impacts between 10% and 30% of individuals worldwide, while , often linked to allergic triggers, affected approximately 260 million people in 2021, leading to about 436,000 deaths annually. Atopic dermatitis, another prevalent allergic condition, had a global prevalence of 129 million cases in 2021. These figures underscore the widespread nature of allergies, with overall sensitization to environmental allergens observed in a substantial portion of the across age groups. Prevalence varies markedly by region, with higher rates generally observed in developed countries compared to developing ones. For example, in , up to 40% of children exhibit evidence of allergic , and food allergies affect about 10% of infants in their first year of life. In contrast, rural African populations report much lower rates compared to developed countries, such as under 1% for food allergies among children and around 7% for , with variations by region and age group. These disparities highlight how socioeconomic development influences allergy distribution, with industrialized nations facing elevated burdens. Urban-rural differences further accentuate these patterns, as is associated with increased allergy prevalence due to factors like environmental and lifestyle changes. Studies show urban residents experiencing higher rates of (e.g., 9.8% vs. 4.3% in rural areas) and other allergic conditions compared to rural counterparts. Allergies typically onset during childhood, with boys showing higher prevalence before , while adult cases demonstrate female predominance, particularly for conditions like and . In low-income areas, true prevalence is likely underestimated due to limited healthcare access and diagnostic challenges, leading to underreporting of cases. The prevalence of allergic diseases has surged since the mid-20th century, often described as an "allergy epidemic" in industrialized nations, with rates in Western countries approximately doubling every 10 to 15 years from the onward. This temporal trend is particularly evident in conditions like , eczema, and hay fever, driven by and lifestyle shifts that have amplified environmental and immunological risk factors. For instance, in and , self-reported allergy prevalence rose from around 10% in the to over 30% by the early , reflecting a broader pattern of increasing across populations. A key explanatory framework for this rise is the , first proposed by Strachan in 1989, which posits that reduced early-life exposure to microbes in highly sanitized, urban environments promotes an imbalance in immune responses, favoring a Th2-biased state that heightens allergy susceptibility. Strachan's analysis of British household data showed that children with more siblings—implying greater exposure—had lower rates of hay fever, suggesting that diminished microbial diversity disrupts the maturation of regulatory T cells and skews immunity toward allergic inflammation. Subsequent studies have reinforced this, linking smaller family sizes, overuse, and indoor living in Western societies to elevated Th2 dominance and atopic disease incidence. Regional variations in allergy trends are increasingly influenced by , which extends seasons and elevates concentrations, exacerbating symptoms in temperate zones. In and , warming temperatures have lengthened seasons by up to 27 days since 1995, with projections indicating a potential 40% increase in production by 2050 under moderate emissions scenarios. Similarly, elevated CO2 levels stimulate higher output from grasses and trees, contributing to more severe and prolonged in urban areas of the Global North. , particularly particulate matter and , interacts with these changes by enhancing potency and airway , while the Western diet—high in processed foods and low in fiber—disrupts gut diversity, further promoting Th2 skewing and systemic allergic responses. This dietary shift, prevalent in affluent regions, reduces beneficial bacteria like , impairing and correlating with higher rates in urban versus rural settings. Recent observations during and after the highlight masking's dual role in allergy dynamics, with prolonged face use linked to flares in contact allergies and irritant among healthcare workers and the general . Studies reported increased allergic reactions to mask materials, such as rubber accelerators in elastic bands, affecting up to 24% of users with symptoms like pruritus and eczema under mask areas. Post-restriction analyses suggest that reduced outdoor exposure during lockdowns may have delayed but intensified seasonal allergy onset upon resumption of normal activities, compounded by alterations from altered hygiene practices. Additionally, post-COVID-19 studies have shown an increased risk of developing allergic conditions like and following infection.

Historical Development

Early Observations and Discoveries

The earliest documented observations of allergic-like symptoms trace back to ancient civilizations, where physicians noted environmental and dietary triggers for respiratory and dermatological distress. Around 400 BCE, , often regarded as the father of medicine, described in his writings seasonal episodes of sneezing, nasal discharge, coughing, and itching eyes among certain individuals, particularly during spring and summer, which are now interpreted as manifestations of pollen-induced hay fever or . These accounts, preserved in the , highlighted individual variability in susceptibility, suggesting an inherent predisposition to such "hostile humors" that exacerbated symptoms in response to airborne irritants like plant pollens. By the , scientific inquiry into these phenomena intensified, shifting from anecdotal reports to experimental validation. British physician Charles Harrison Blackley, himself a hay fever sufferer, conducted groundbreaking self-experiments in 1873 that definitively linked to the condition. Using innovative techniques such as kite- and balloon-based sampling to collect airborne at various altitudes, Blackley demonstrated that exposure to grass grains provoked immediate symptoms including sneezing, lacrimation, and . He further pioneered skin prick testing by abrading his own skin and applying extracts, observing localized wheal-and-flare reactions that confirmed as the etiologic agent of "catarrhus aestivus" (hay fever), challenging prevailing notions of dust or miasma as causes. Concurrently, foundational immunological concepts emerged that would underpin allergy understanding. In 1897, German scientist introduced his side-chain theory in a series of lectures and publications, proposing that cells bear specific "side-chain" receptors capable of binding complementary toxins or antigens, thereby triggering protective responses through proliferation and release of these chains as antibodies. This receptor-ligand model, initially developed to explain immunity to infections, laid the theoretical groundwork for later interpretations of allergies as reactions involving mismatched or exaggerated bindings. Ehrlich's ideas, recognized for their prescience, influenced subsequent research by framing allergic phenomena within cellular chemistry. The turn of the brought pivotal discoveries on severe allergic responses and initial therapeutic advances. In 1902, French physiologist and his colleague Paul Portier observed during experiments that dogs sensitized to extracts (Physalia) via an initial injection developed catastrophic shock—marked by respiratory failure, cardiovascular collapse, and death—upon a second, seemingly innocuous dose administered weeks later. Richet termed this state "" (without protection), distinguishing it from expected immunity and describing it as a paradoxical sensitization; this work, which revealed the dual-edged nature of immune memory, earned Richet the 1913 in or . Shortly thereafter, in 1903, American physicians Jesse G.M. Bullowa and David M. Kaplan demonstrated the efficacy of subcutaneous adrenaline (epinephrine) chloride injections in aborting acute paroxysms, reporting rapid bronchodilation and symptom relief within minutes in patients unresponsive to other remedies, thus establishing adrenaline as a cornerstone for managing allergic emergencies.

Modern Advances and Milestones

In the mid-20th century, a pivotal breakthrough came with the identification of (IgE) as the key antibody mediating allergic reactions. In 1966, Kimishige and Teruko Ishizaka isolated and characterized IgE from the serum of allergic individuals, demonstrating its role in reaginic activity and . This discovery enabled the development of serologic testing methods, such as the (RAST) introduced in the late 1960s, which allowed for detection of allergen-specific IgE antibodies without relying solely on skin prick tests. Allergen immunotherapy, first proposed by Leonard Noon in 1911 through subcutaneous injections of grass pollen extracts, underwent significant refinements in the 1970s and 1980s. During this period, randomized controlled trials established its efficacy for various allergens, including house dust mites and insect s, while standardization of extract potency—through methods like equivalence and intradermal bioassays—improved dosing safety and reproducibility. Additionally, reports of fatal anaphylactic reactions in the 1980s prompted regulatory changes, such as the U.S. Food and Drug Administration's requirements for immunotherapy protocols, enhancing overall . The late 20th and early 21st centuries saw advances in targeted biologics and genetic insights. Omalizumab, a monoclonal antibody that binds free IgE to prevent its interaction with mast cells and basophils, received U.S. Food and Drug Administration approval in 2003 for moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids. In 2024, omalizumab received FDA approval for reducing allergic reactions, including anaphylaxis, to multiple foods after accidental exposure in patients aged 1 year and older. In genetics, candidate gene studies in the 1990s identified initial susceptibility loci, such as those linked to elevated serum IgE levels and bronchial hyperresponsiveness on chromosome 5q31, laying groundwork for understanding atopic inheritance. The 2010s brought genome-wide association studies (GWAS), which pinpointed multiple loci—including IL33, IL1RL1, and the 17q21 region (ORMDL3)—shared across asthma, allergic rhinitis, and eczema, revealing polygenic risks and pathways like epithelial barrier function. Clinical guidelines also evolved to incorporate these milestones. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, first published in 2001, classified by duration and severity while emphasizing its link to , promoting integrated management strategies. Updated in 2020, ARIA integrated and digital tools for personalized care. Similarly, the 2015 Learning Early About Peanut Allergy (LEAP) trial demonstrated that early peanut introduction in high-risk infants reduced incidence by 81% at age 5, shifting prevention paradigms toward proactive exposure rather than avoidance.

Ongoing Research

Emerging Therapies

Emerging therapies for allergies encompass innovative biologics, immunotherapies, microbiome interventions, gene editing approaches, and advanced delivery systems, many of which are in advanced clinical trials or preclinical stages as of 2025. These treatments aim to target underlying immune mechanisms more precisely than traditional options, potentially offering long-term tolerance or reduced with fewer side effects. Dupilumab, a monoclonal antibody that inhibits signaling through the interleukin-4 receptor alpha subunit to block both IL-4 and IL-13 pathways, has expanded beyond its initial 2017 approvals for moderate-to-severe and . Clinical trials have demonstrated its efficacy in reducing Th2-driven inflammation, with phase III studies showing 69-72% improvement in eczema area and severity index scores over 16 weeks in patients. In severe , it reduced exacerbations by up to 65.8% in patients with high eosinophil counts. Expansions include approvals for chronic rhinosinusitis with nasal polyps and promising results in , where phase II trials reported 45% histological improvement. Tezepelumab, targeting (TSLP) to address broader airway inflammation, received FDA approval in 2021 for add-on maintenance therapy in severe patients aged 12 and older, regardless of eosinophil levels. In 2025, it gained approval for chronic with nasal polyps in the same age group, based on phase III trial data showing significant reductions in polyp severity and near-elimination of the need for sinus surgery compared to . Real-world studies as of 2025 confirm its effectiveness in diverse severe populations, with reductions in exacerbations and improved lung function. Epicutaneous immunotherapy represents a vaccine-like approach for food allergies, delivering allergens via skin patches to induce tolerance. Viaskin Peanut, a 250 μg protein patch, completed phase III trials in 2023, demonstrating superior desensitization in toddlers aged 1-3 years with , where 67% achieved a response (increased eliciting dose) after 12 months compared to 33.5% on . Long-term extensions confirm its safety profile, with high adherence and modest treatment responses, particularly in younger children. Microbiome therapies explore modulation to prevent or mitigate allergic responses. Fecal microbiota transplantation (FMT) has shown preclinical promise in reducing IgE production and Th2 in neonatal mouse models of . A phase I trial evaluating oral encapsulated FMT for was completed, assessing safety and efficacy, though detailed results indicate potential for immune regulation without widespread adoption yet. Specific like have been associated with higher and better engraftment in microbiome interventions, with ongoing trials investigating their role in allergy prevention. Gene editing via / targets IgE-mediated pathways in preclinical models of allergic diseases. In , knockout of the in human + T cells reduced IL-13 production by over 50%, and in mouse models, it prevented by lowering Th2 cytokines. Similar approaches in models inhibit IL-13 in T cells, suggesting potential for editing immune cells to disrupt IgE class-switching, though applications remain limited to animal and cell studies. Nanoparticle delivery systems enhance safer by encapsulating antigens for targeted immune modulation. Allergen-specific mRNA-lipid administered prophylactically or therapeutically in mouse models of experimental allergy reduced allergic responses and alleviated established symptoms by reshaping . Poly(lactic-co-glycolic) acid have demonstrated suppression of allergen-specific IgE and promotion of tolerogenic phenotypes in preclinical settings, with clinical trials underway to minimize adverse effects in humans.

Influencing Factors and Future Directions

Research into the gut microbiome has revealed significant links between —an imbalance in microbial composition—and the development of allergic diseases, including food allergies and atopic conditions. Studies indicate that early-life disruptions in maturation, such as those caused by use or cesarean delivery, impair and elevate allergy risk by altering regulatory T-cell function and short-chain production. reduces beneficial bacteria like and , which normally suppress Th2-dominated immune responses central to allergies. In the 2020s, clinical trials have explored fecal transplantation (FMT) as a therapeutic approach to restore microbial balance in allergy patients, with ongoing phase II studies evaluating the safety and potential efficacy of oral encapsulated fecal transplantation from non-allergic donors in reducing symptoms of in adolescents and adults. These trials highlight FMT's potential to modulate gut immunity and decrease IgE levels, though larger randomized controlled studies are needed to confirm long-term benefits. Climate change and environmental are projected to exacerbate the global burden of allergies through extended seasons, increased aeroallergen potency, and synergistic effects with pollutants like particulate matter. Rising CO2 levels enhance plant allergen production, while warmer temperatures prolong pollination periods, potentially increasing cases by 20-50% in vulnerable regions by mid-century, according to predictive models. , including and nitrogen oxides, acts as an adjuvant amplifying IgE-mediated responses and epithelial barrier disruption, with epidemiological projections estimating heightened exacerbations in urban areas. Future adaptation strategies emphasize integrated modeling to forecast regional burdens, incorporating climate data with health surveillance to guide urban greening and emission controls that mitigate allergen- interactions. Advances in personalized medicine are leveraging artificial intelligence (AI) to integrate genomics and exposome data for precise allergy risk prediction and tailored interventions. AI algorithms analyze multi-omics profiles—combining genetic variants like those in the filaggrin gene with environmental exposures such as air quality and diet—to generate individualized risk scores, enabling early identification of at-risk individuals with up to 80% accuracy in cohort studies. The exposome, encompassing lifetime environmental influences, is quantified via wearable sensors and biomarkers, with machine learning models predicting allergy trajectories by simulating gene-environment interactions. This approach supports customized immunotherapy dosing and preventive strategies, shifting from reactive to proactive care in high-risk populations. Global disparities in allergy research persist, with understudied populations in developing countries facing higher unmet needs due to limited epidemiological data and resource constraints. In low- and middle-income nations, where urbanization and dietary shifts drive rising allergy prevalence, studies reveal gaps in genomic and environmental profiling compared to high-income settings, hindering equitable advancements. Efforts to address these include collaborative initiatives expanding cohort studies in Africa and Asia, focusing on local allergens like tropical pollens and parasitic co-exposures that modulate allergy phenotypes. Enhanced funding and international partnerships are essential to bridge these divides, ensuring research reflects diverse genetic and socioeconomic contexts. Vaccine development for common allergens is advancing toward innovative platforms like mRNA technology to induce long-term tolerance without traditional immunotherapy's limitations. Preclinical models demonstrate mRNA vaccines encoding hypoallergenic variants of or proteins can suppress Th2 responses and prevent in animal studies. Phase I trials of novel constructs, such as synthetic peptides for , show safety and , paving the way for broader applications against food and respiratory allergens. Future directions emphasize multi-allergen formulations to streamline prophylaxis, potentially integrating with routine vaccinations for scalable global impact.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.